Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer. (1st December 2017)

• Record Type: Journal Article
• Authors: Hoang, Bryan; Ernsting, Mark J.; Tang, Wei-Hsin Sophia; Bteich, Joseph; Undzys, Elijus; Kiyota, Taira; Li, Shyh-Dar
• Is Part Of: Cancer letters. Volume 410(2017)
• Page Start: 169
• Page End: 179
• Publication Date: 2017-12-01
• Subjects: Cabazitaxel -- Drug-resistance -- Nanoparticles -- Prostate cancer -- Bone metastasis; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2017.09.029
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Effective treatment of metastatic castration resistant prostate cancer (mCRPC) remains an unmet challenge. Cabazitaxel (CBZ) is approved for mCRPC after docetaxel (DTX) failure, but the improvement in survival is only moderate (∼2 months) and patients suffer from significant side effects. Here, we report the development of a polymer based delivery system for CBZ to improve its safety and efficacy against DTX-resistant mCRPC. CBZ was conjugated to a carboxymethylcellulose-based polymer (Cellax-CBZ), which self-assembled into ∼100 nm particles in saline and exhibited sustained drug release in serum at 10%/day. Cellax-CBZ delivered 157-fold higher CBZ to PC3-RES prostate tumor in mice and could be safely administered at a 25-fold higher dose compared to free CBZ, resulting in superior tumor inhibition in multiple mice models of DTX-resistant CRPC. In a metastatic bone model of CRPC, Cellax-CBZ significantly improves overall survival with a 70% long-term survival rate to day 120, while mice treated with free CBZ had a median survival of 40 days. Cellax-CBZ induced mild and reversible neutropenia in mice but no other tissue damage. Cellax-CBZ showed significant potential for improving therapy of mCRPC over clinically approved CBZ. Highlights: Cellax-CBZ improved drug delivery to the tumor by ~160-fold compared to free CBZ. Cellax-CBZ cured 70% of mice bearing bone metastases of resistant prostate tumor. Cellax-CBZ only induced mild neutropenia but no other tissue damage.